← SpyGlass Pharma, Inc. (SGP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SpyGlass Pharma, Inc. (SGP)
Surgical & Medical Instruments & Apparatus · market cap $958M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
SpyGlass Pharma, Inc. (SGP) is a clinical-stage ophthalmic company focused exclusively on cataract-related indications, with a market cap of ~$669M and ~$239M in cash providing an estimated 52.9 months of runway. Its lead asset, the Bimatoprost Implant System, is in Phase 3 for cataract, alongside a Phase 3 Timolol Maleate ophthalmic solution and a Phase 2 high-dose variant of the implant — all targeting cataract.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bimatoprost Implant System | Phase 3 | Cataract |
| Timolol Maleate Ophthalmic Solution, 0.5% | Phase 3 | Cataract |
| Bimatoprost Implant System (High Dose) | Phase 2 | Cataract |
Price & technical context
3-month
+34.6%
6-month
+14.4%
12-month
—
52-wk range
$17.56–$29.68
vs 50-day MA
-1.6%
vs 200-day MA
—
Realized vol
61.4%
Max drawdown
-40.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SGP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.